Purpose Marijuana Opportunities Fund Provides Exposure to North American and Global Pot Stocks MJJ ETF Has Likely Bottomed and Could Be an Excellent Value Buy at These Levels Purpose Marijuana... read more →
Jim Cramer Says This Cannabis Stock is Being Unfairly Dragged Down By Cannabis ETFs The Mad Money Host Gave the Stock a 'Booyah' and Said Investors Should Consider Owning It... read more →
Now That the Bottom is Finally In, These Oversold Pot Stocks Could Make Attractive Investments Some of These Cannabis Stocks Are Undervalued While Others Are Headed for the Pot Stock... read more →
Welcome to the Cannabis Countdown. In this week’s rendition, we’ll recap and countdown the top 10 marijuana stock news stories for the week of November 18th – 24th, 2019. Without further... read more →
If Elected, 2020 Presidential Candidate Bernie Sanders Vows to Legalize Cannabis in First 100 Days in Office This past Thursday at 4:20 pm EST, 2020 Presidential Candidate Senator Bernie Sanders... read more →
Market Downturn Causes 7 Cannabis Stocks to Drop Off the $1 Billion+ Market Cap List Currently Only These 10 Marijuana Stocks Remain Above the Coveted Threshold At the height of... read more →
As Shorts Continue to Pile In and Regulatory Issues Fade, The Potential for a Massive Short Squeeze is Heightened The cannabis market is famous for making legendary runs and in... read more →
Welcome to the Cannabis Countdown. In this week’s rendition, we’ll recap and countdown the top 10 marijuana stock news stories for the week of September 23rd – 29th, 2019. Without further ado,... read more →
GW Pharma Receives EU Approval for CBD-Based Epilepsy Drug Epidyolex The Cannabis Catch-Up is a convenient and easy to read daily summary of the top cannabis stock news. We’ve scanned the newsfeeds... read more →
GW Pharmaceuticals (NASDAQ: GWPH) announced this morning that the European Commission has approved the marketing authorization for the company's plant-derived CBD-based epilepsy drug Epidyolex. Epidyolex was created to treat seizures... read more →
